Header

Melanoma Clinical Trials

Category:Adult
Status:Active

Displaying all 12 trials

High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B or ipilimumab works compared with pembrolizumab in treating patients with stage III-IV melanoma that has be...

Diagnosis: Melanoma

Phase: 3

Protocol Number: 16-703

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating pati...

Diagnosis: Melanoma, Cutaneous Skin Cancer

Phase: 2 / 3

Protocol Number: 15-724

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies...

Diagnosis: Melanoma

Phase: 2

Protocol Number: 13-465

A Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab by Itself

This is an open-label, multi-site Phase 2 study of Nivolumab combined with Ipilimumab followed by Nivolumab monotherapy for the treatment of subjects with Melanoma metastatic to the brain. Patients...

Diagnosis: Melanoma

Phase: 2

Protocol Number: 15-096

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. T...

Diagnosis: Melanoma

Phase: 2

Protocol Number: 15-012

Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma

This research study is studying a combination of two drugs as a possible treatment for Leptomeningeal Metastases from Melanoma. The names of the study interventions involved in this study are: - Ip...

Diagnosis: Melanoma

Phase: 2

Protocol Number: 16-136

RTA 408 Capsules in Patients With Melanoma - REVEAL

Malignant melanoma is a leading cause of death from cutaneous malignancies, accounting for approximately three-fourths of all skin cancer deaths. For metastatic or unresectable melanomas, standard ...

Diagnosis: Melanoma

Phase: 1 / 2

Protocol Number: 15-215

Dendritic Cell Activating Scaffold in Melanoma

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of investigational melanoma vaccines. Phase I studies also try to define the appropriate dose of the investi...

Diagnosis: Melanoma

Phase: 1

Protocol Number: 12-306

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

This is an open label, phase I trial, testing the combination of Tremelimumab and MEDI3617 in patients with metastatic melanoma.

Diagnosis: Melanoma

Phase: 1

Protocol Number: 13-613

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

This randomized phase I trial studies the side effects and best way to give ipilimumab with or without dabrafenib, trametinib and/or nivolumab in treating patients with melanoma that has spread to ...

Diagnosis: Melanoma

Phase: 1

Protocol Number: 13-304

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

The purpose of this study is to determine the initial safety profile of the combination treatments (immune checkpoint inhibitors [nivolumab, ipilimumab] with investigational drugs [TAK-580, TAK-202...

Diagnosis: Melanoma

Phase:

Protocol Number: 16-269

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The intervention...

Diagnosis: Melanoma

Phase:

Protocol Number: 17-030

'